Release Details

JERUSALEM--(BUSINESS WIRE)--Nov. 30, 2012-- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, today announced that its management team will be presenting at the 2012 Fifth Annual LD MICRO Conference at the Luxe Sunset Bel Air Hotel in Los Angeles.

The Chief Executive Officer of BioLineRx, Dr. Kinneret Savitsky, and the Company’s Chief Financial and Operating Officer, Mr. Philip Serlin, are scheduled to present at 11:30 a.m. PT on Wednesday, December 5^th. The presentation will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: webcast link. For those unable to listen to the live presentation, an archive of the event will also be available for 90 days.

Investors attending the conference that wish to meet with Dr. Savitsky or Mr. Serlin for a one-on-one meeting should notify their LD Micro contact.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of six clinical stage candidates: BL-1020 for schizophrenia is currently undergoing a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development, BL-7040 for treating inflammatory bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has completed Phase I. In addition, BioLineRx has eight products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government’s Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization.

For more information on BioLineRx, please visit www.biolinerx.com.

Source: BioLineRx Ltd.

KCSA Strategic Communications
Garth Russell / Todd Fromer
1 212-896-1250 / 1 212-896-1250
grussell@kcsa.com / tfromer@kcsa.com
or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il